Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-Part, Phase I, Open-label, Single-Dose, Sequential Randomized Crossover Study of New Acalabrutinib Tablet in Healthy Subjects to Evaluate Relative Bioavailability, Proton Pump Inhibitor (Rabeprazole) Effect, Food Effect and Particle Size Effect

Next Previous
X
Search
Trial Profile

A 2-Part, Phase I, Open-label, Single-Dose, Sequential Randomized Crossover Study of New Acalabrutinib Tablet in Healthy Subjects to Evaluate Relative Bioavailability, Proton Pump Inhibitor (Rabeprazole) Effect, Food Effect and Particle Size Effect

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Feb 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; Acalabrutinib (Primary) ; Acalabrutinib (Primary) ; Rabeprazole
  • Indications B-cell lymphoma
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca

    • Most Recent Events

    • 22 Feb 2023 According to AstraZeneca media release, the Calquence (acalbrutinib) has been approved in the European Union (EU) for adults with chronic lymphocytic leukemia (CLL). The approval was based on the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) and is based on the results from the ELEVATE-PLUS trials.
    • 01 Nov 2022 Results from NCT04768985, NCT04488016 and NCT04564040; assessing a new Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors, published in the Clinical Pharmacology in Drug Development
    • 05 Aug 2022 According to an AstraZeneca media release, US FDA has approved new tablet formulation of CALQUENCE (acalabrutinib) for all current indications. The approval was based on results from this and two other phase I trials (ELEVATE PLUS).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top